Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

NCT06942234 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Inoperable Locally Advanced HER2-Negative Breast Cancer
Metastatic HER2-Negative Breast Cancer

Interventions

DRUG: JSKN016
DRUG: Capecitabine
DRUG: Paclitaxel (albumin bound)
DRUG: Eribulin
DRUG: Pembrolizumab

Sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd